Company Overview and News

 
Zandu Realty to turn ex-date for merger

2018-05-22 thehindubusinessline
Shares of Zandu Realty will turn ex-date on Thursday for the proposed amalgamation with Emami Infrastructure. The latter will issue seven shares for every one share of ₹100 each held in Zandu Realty. Investors wishing to receive Emami shares need to own Zandu Realty shares by Wednesday, as the company has fixed May 25 as the record date. While the shares of Emami jumped 12.3 per cent to ₹278, those of Zandu gained 6.
533218 ZANDUREALT EMAMIINFRA PQRTY PETRONET 506720 532522

 
Zandu Realty Limited - Suspension of trading in equity shares

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZANDUREALT 506720

22
Market Live: Sensex in the red, rupee sinks 35 paise; BJP leads in Karnataka but away from half-way mark

2018-05-15 moneycontrol
Earnings: Pharma major Lupin has posted a loss of Rs 783.5 crore for the quarter ended March 2018, due to one-time loss of Rs 1,464.3 crore on Gavis Group acquisition.
PWQFY 539150 500325 EMAMIINFRA BHUSANSTL RELIANCE PNCINFRA 532810 539437 500470 IDFCBANK RIGD 500570 SNOWMAN TATAMOTORS 500055 RLNIY INDIGO IBN 532605 JBMA 538635 539448 PFC ICICIBANK 533218 ZANDUREALT TTST INDIANHUME TATASTEEL TATLY 532174 504741 506720 TTM

22
Market Live: Sensex off day#39;s high, midcaps weak; BJP leads in Karnataka but away from half-way mark

2018-05-15 moneycontrol
Market Update: The market lost more than 3/4th of its gains in afternoon trade. The BJP is likely to emerge as the single largest party in the Karnataka Assembly as it leads in 106 constituencies but is slightly away from its half-way mark.
PWQFY 500325 EMAMIINFRA BHUSANSTL RELIANCE 532810 539437 500470 IDFCBANK RIGD 507747 TTKHEALTH 500570 TATAMOTORS 500055 RLNIY INDIGO IBN 539448 PFC ICICIBANK 533218 ZANDUREALT TTST TATASTEEL TATLY 532174 506720 TTM

9
Market Live: Sensex, Nifty Bank off day#39;s high; BJP maintains lead in Karnataka

2018-05-15 moneycontrol
Market Outlook: VK Sharma, Head Private Client Group & Capital Market Strategy at HDFC Securities said going by the trends and the leads so far, with BJP emerging as a the single largest party, markets are relieved. Even if the Congress forms the Government with the help of the JDS, the markets won’t be perturbed.
533218 500470 ZANDUREALT TTST TATASTEEL TATLY EMAMIINFRA BHUSANSTL 507747 TTKHEALTH 506720 500055

 
Zandu Realty Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZANDUREALT 506720

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...